Skip to main content
Clinical Trials/NCT00441883
NCT00441883
Completed
Phase 2

A Phase 2, 28 Day Parallel-Group, Double-Masked, Dose-Finding Study Comparing the Safety and Efficacy of PF-03187207 to Latanoprost

Bausch & Lomb Incorporated1 site in 1 country176 target enrollmentStarted: March 2007Last updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
176
Locations
1
Primary Endpoint
Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28

Overview

Brief Summary

This study will evaluate the safety and efficacy of PF 03187207.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of primary open angle glaucoma (including pigmentary or pseudoexfoliative) or ocular hypertension in one or both eyes

Exclusion Criteria

  • Closed or barely open anterior chamber angle or a history of acute angle closure in either eye

Arms & Interventions

PF-03187207 and Latanoprost Vehicle

Experimental

One drop of each, once daily in study eye for 28 days

Intervention: PF-03187207 and Latanoprost Vehicle (Drug)

Latanoprost 0.005% and PF-03187207 Vehicle

Active Comparator

One drop of each, once daily in study eye for 28 days

Intervention: Latanoprost 0.005% and PF-03187207 Vehicle (Drug)

Outcomes

Primary Outcomes

Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28

Time Frame: Baseline, 28 days

Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. Diurnal IOP, defined as the mean IOP over the day based on values obtained at 8 AM, 10 AM, 1 PM, and 4 PM, was calculated for each visit. Both eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.

Secondary Outcomes

  • Change From Baseline in Mean Intraocular Pressure IOP at the Day 7, 14, and 21 Visits(Baseline, Day 7, Day 14, and Day 21)
  • Percentage of Participants With Intraocular Pressure (IOP) Less Than or Equal to 18 mmHg at Any Visit Through Day 28(28 days)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials